Curanex Pharmaceuticals Inc Operating Lease, Right-of-Use Asset, Amortization Expense
Curanex Pharmaceuticals Inc (CURX) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $71.68 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-14
- Curanex Pharmaceuticals Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $36.64K, a 143.75% increase year-over-year.
- Curanex Pharmaceuticals Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $35.04K, a 139.47% increase year-over-year.
- Curanex Pharmaceuticals Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $34.29K.
- Curanex Pharmaceuticals Inc operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $15.44K.
- Curanex Pharmaceuticals Inc operating lease, right-of-use asset, amortization expense for fiscal 2025 was $79.40K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $36.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $71.68K 10-Q · filed 2026-08-14 | $105.97K derived: sum of 3 quarters · filed 2026-08-14 | $121.41K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $35.04K 10-Q · filed 2026-05-14 | $69.33K derived: sum of 2 quarters · filed 2026-05-14 | $84.77K derived: sum of 3 quarters · filed 2026-05-14 | $99.80K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $34.29K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $49.73K derived: sum of 2 quarters · filed 2026-03-30 | $64.76K derived: sum of 3 quarters · filed 2026-08-14 | $79.40K 10-K · filed 2026-03-30 |
| 2025-09-30 | $15.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $30.47K derived: sum of 2 quarters · filed 2026-08-14 | $45.10K 10-Q · filed 2025-11-17 | |
| 2025-06-30 | $15.03K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $29.66K 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | $14.63K 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |